[
  {
    "ts": "2025-09-15T13:00:00+00:00",
    "headline": "Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test",
    "summary": "PRESS RELEASE - 09/15/2025, 09:00 AM EDT Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test First-ever fully automated, sample-to-result, cartridge-based companion diagnostic test approved in the US for colorectal cancer patients Itasca (IL), United States, 15 September 2025 – Biocartis Group of Companies (“Biocartis”), an innovative molecular diagnostics company, is pleased to announce that its Idylla™ CDx MSI Test developed in partnership with Bristol Myers Squibb, has received the f",
    "url": "https://finance.yahoo.com/news/press-release-biocartis-nv-biocartis-130000684.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "85833481-b35c-3956-97c5-13bb09399725",
      "content": {
        "id": "85833481-b35c-3956-97c5-13bb09399725",
        "contentType": "STORY",
        "title": "Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test",
        "description": "",
        "summary": "PRESS RELEASE - 09/15/2025, 09:00 AM EDT Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test First-ever fully automated, sample-to-result, cartridge-based companion diagnostic test approved in the US for colorectal cancer patients Itasca (IL), United States, 15 September 2025 – Biocartis Group of Companies (“Biocartis”), an innovative molecular diagnostics company, is pleased to announce that its Idylla™ CDx MSI Test developed in partnership with Bristol Myers Squibb, has received the f",
        "pubDate": "2025-09-15T13:00:00Z",
        "displayTime": "2025-09-15T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/e90ef6263fe38d5648a6b23302eda3be",
          "originalWidth": 1000,
          "originalHeight": 1000,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RPf9UOw5.bQC_iSdx6Bpnw--~B/aD0xMDAwO3c9MTAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/e90ef6263fe38d5648a6b23302eda3be.cf.webp",
              "width": 1000,
              "height": 1000,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QMV_3P9awh_c8qnCdfnCoQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/e90ef6263fe38d5648a6b23302eda3be.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/press-release-biocartis-nv-biocartis-130000684.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/press-release-biocartis-nv-biocartis-130000684.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-15T11:00:00+00:00",
    "headline": "Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma",
    "summary": "First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab[212Pb]VMT01 3.0 mCi single agent dose Cohort re-opened SEATTLE, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (\"Perspective\" or the \"Company\") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted",
    "url": "https://finance.yahoo.com/news/perspective-therapeutics-progresses-dose-finding-110000210.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "dc33273d-441b-3847-894e-ca74dbc037d9",
      "content": {
        "id": "dc33273d-441b-3847-894e-ca74dbc037d9",
        "contentType": "STORY",
        "title": "Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma",
        "description": "",
        "summary": "First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab[212Pb]VMT01 3.0 mCi single agent dose Cohort re-opened SEATTLE, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (\"Perspective\" or the \"Company\") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted",
        "pubDate": "2025-09-15T11:00:00Z",
        "displayTime": "2025-09-15T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/838f217da615df0b6c09f0e2557cd05f",
          "originalWidth": 624,
          "originalHeight": 131,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GNGkjH__517mGnV_oqTm_Q--~B/aD0xMzE7dz02MjQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/838f217da615df0b6c09f0e2557cd05f.cf.webp",
              "width": 624,
              "height": 131,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1hW.gqtaupVUjQ2Q8sbZ8w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/838f217da615df0b6c09f0e2557cd05f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/perspective-therapeutics-progresses-dose-finding-110000210.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/perspective-therapeutics-progresses-dose-finding-110000210.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CATX"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-15T10:55:07+00:00",
    "headline": "How Bad Is This Sector’s Health Scare?",
    "summary": "Do not buy healthcare fund if you are allergic to any of its ingredients.  After a rough stretch, some investors were prepared to ignore the warning label and bet on the beaten-down sector this year.  For example, asset manager Janus Henderson pointed out in January that an index of health stocks had trailed the S&P 500 by an unprecedented 53 percentage points over two years and looked “deeply undervalued.”",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-09-15-2025/card/-how-bad-is-this-sector-s-health-scare--6kDpz8zREoRADnqxXzUW?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "63356883-f8c9-3eea-9b6e-2c9481148fce",
      "content": {
        "id": "63356883-f8c9-3eea-9b6e-2c9481148fce",
        "contentType": "STORY",
        "title": "How Bad Is This Sector’s Health Scare?",
        "description": "",
        "summary": "Do not buy healthcare fund if you are allergic to any of its ingredients.  After a rough stretch, some investors were prepared to ignore the warning label and bet on the beaten-down sector this year.  For example, asset manager Janus Henderson pointed out in January that an index of health stocks had trailed the S&P 500 by an unprecedented 53 percentage points over two years and looked “deeply undervalued.”",
        "pubDate": "2025-09-15T10:55:07Z",
        "displayTime": "2025-09-15T10:55:07Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/63356883-f8c9-3eea-9b6e-2c9481148fce/how-bad-is-this-sector%E2%80%99s.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/09c4afa468ee78de660960db7bacdaea",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xQZDDtqD66RN80L.tLwbiA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/09c4afa468ee78de660960db7bacdaea.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mVhUhJja179LExPUVmXi8Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/09c4afa468ee78de660960db7bacdaea.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-09-15-2025/card/-how-bad-is-this-sector-s-health-scare--6kDpz8zREoRADnqxXzUW?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]